Inventor · disambiguated record
Zhengtao Li
Also filed as: LI ZHENGTAO
7 granted patents·9 pending applications·20 citations·filing 2014–2025
80Inventor score
Files withSCRIPPS RESEARCH INST5DIZAL JIANGSU PHARMACEUTICAL CO LTD4TUOJIE BIOTECH SHANGHAI CO LTD4HAINAN SIMCERE PHARMACEUTICAL CO LTD1HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD1
Top patents by PatentIndex Score
16 records- 0193US10822334B2ErbB receptor inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Nov 3, 2020·4 cites·6 claims
- 0287US11634451B2Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotidesSCRIPPS RESEARCH INST·Filed 2019·Granted Apr 25, 2023·3 cites·52 claims
- 0387US11007198B2ErbB/BTK inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted May 18, 2021·2 cites·5 claims
- 0487US10626138B2Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotidesSCRIPPS RESEARCH INST·Filed 2014·Granted Apr 21, 2020·10 cites·19 claims
- 0584US12281137B2Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotidesSCRIPPS RESEARCH INST·Filed 2023·Granted Apr 22, 2025·0 cites·35 claims
- 0682US11504375B2ErbB/BTK inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2021·Granted Nov 22, 2022·1 cites·23 claims
- 0774US2025171488A1Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotidesSCRIPPS RESEARCH INST·Filed 2025·Application pending·0 cites
- 0871US2020017540A1Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotidesSCRIPPS RESEARCH INST·Filed 2019·Application pending·0 cites
- 0961US11447492B2ERBB receptor inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Sep 20, 2022·0 cites·15 claims
- 1057US2025042896A1Polycyclic compound as cbl-b inhibitorHAINAN SIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1154US2024226107A1Ubiquitin-specific protease 1 (usp1) inhibitorSIMCERE ZAIMING PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1253US2025154131A1Pyrrolidine antiviral compoundHAINAN SIMCERE PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1352US2024209004A1BORIC ACID DERIVATIVE ACTING AS Beta-LACTAMASE INHIBITORTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 1449US2023250095A1Benzimidazole derivatives, preparation method therefor and medical use thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 1540US2022380385A1Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2020·Application pending·0 cites
- 1637US2022073521A1Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereofTUOJIE BIOTECH SHANGHAI CO LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Zhengtao Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →